{"schema_version":"1.0","type":"article","title":"【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】","url":"https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.md","lang":"zh-Hant","date":"2026-06-20","publish_at":"2026-06-20T08:00:00+08:00","updated_at":"2026-06-20","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI","BD","臨床數據","生技投資","製藥巨頭"],"summary":"一家臨床階段 Biotech，沒有藥品銷售收入，卻在一年內做出 12 億美元級別的淨利。","key_points":[],"facts":[],"sections":["01｜0 收入，卻做出 12 億美元級淨利","02｜RAIN 國庫策略：Enlivex 想用幣圈替藥圈造血","03｜為什麼 Biotech 會想走這條路？因為融資環境太殘酷","04｜Allocetra™ 才是 Enlivex 真正的藥物故事","05｜二級市場為什麼沒有完全買單？","06｜Biotech 炒幣，是天才策略還是危險信號？","07｜這件事對台灣 Biotech 有什麼啟示？","結語｜Biotech 可以找新錢，但不能忘記自己終究要靠藥證明"],"references":[{"title":"[1] Enlivex Therapeutics","source":"Investor relations and company filings:","date":"","url":"https://enlivex.com/investors/"},{"title":"[2] GlobeNewswire","source":"Enlivex company news releases:","date":"","url":"https://www.globenewswire.com/search/organization/Enlivex%2520Therapeutics"}],"images":[{"alt":"Facebook 原圖：【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】（圖 1）","url":"https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury/facebook-01.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury/cover-generated.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-20）。【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】。https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-20-enlivex-rain-token-biotech-treasury-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}